Numerous strategies to target HER2 molecular alterations in NSCLC have been tested, including conventional chemotherapy, anti-HER2 antibodies, TKIs and, more recently, antibody-drug conjugates (ADC) (Table 3 and Figure 4). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.